UK Collaborative Trial of Ovarian Cancer Screening Study Results Published

Press Release · December 17, 2015

Today, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) reported results of its 14 year-long study, which showed that ovarian cancer screening may reduce ovarian cancer mortality by up to 20%.

UKCTOCS is the largest ovarian cancer screening trial ever performed on a general population of postmenopausal women who are not considered at high risk for ovarian cancer. A total of 202,638 women from across the United Kingdom participated. Women were split into three groups – no screening, annual CA-125 screening with transvaginal ultrasound scan as a second line test, and annual transvaginal ultrasound alone.

“This study is showing promise that we can reduce the number of deaths from ovarian cancer by screening average risk women for ovarian cancer,” said Dr. Saul Rivkin, MD, Founder and Chairman of the Rivkin Center for Ovarian Cancer. More research needs to be done before CA-125 testing becomes a standard screening tool for all women who do not have a strong family history of ovarian and breast cancer. Clinical screening guidelines already exist for women at high risk of ovarian cancer.

“The results of the UKCTOCS trial underscore the complexity of screening for ovarian cancer. Using state of the art methods the study hints that, with longer follow-up, multi-modality screening may be of benefit. We need more time for the data to mature to provide a definitive answer,” Rivkin Center Scientific and Medical Director Nora Disis, MD said about the study.

Read the Medpage Today article.
Read the press release published by The Lancet.
Watch the full announcement from UK Collaborative Trial of Ovarian Cancer Screening on YouTube.